GINMU >

ブラウズ : 著者 Kaji, Kosuke

発行日	タイトル	著者
2023年4月	A Combination of an Angiotensin II Receptor and a Neprilysin Inhibitor Attenuates Liver Fibrosis by Preventing Hepatic Stellate Cell Activation	Suzuki, Junya; Kaji, Kosuke; Nishimura, Norihisa; Kubo, Takahiro; Tomooka, Fumimasa; Shibamoto, Akihiko; Iwai, Satoshi; Tsuji, Yuki; Fujinaga, Yukihisa; Kitagawa, Koh; Namisaki, Tadashi; Akahane, Takemi; Yoshiji, Hitoshi
2018年10月10日	Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein.	Saikawa, Soichiro; Kaji, Kosuke; Nishimura, Norihisa; Seki, Kenichiro; Sato, Shinya; Nakanishi, Keisuke; Kitagawa, Koh; Kawaratani, Hideto; Kitade, Mitsuteru; Moriya, Kei; Namisaki, Tadashi; Mitoro, Akira; Yoshiji, Hitoshi
2021年12月	Angiotensin Receptor Blockers Potentiate the Protective Effect of Branched-Chain Amino Acids on Skeletal Muscle Atrophy in Cirrhotic Rats	Takeda, Soichi; Kaji, Kosuke; Nishimura, Norihisa; Enomoto, Masahide; Fujimoto, Yuki; Murata, Koji; Takaya, Hiroaki; Kawaratani, Hideto; Moriya, Kei; Namisaki, Tadashi; Akahane, Takemi; Yoshiji, Hitoshi
2020年10月14日	Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells.	Kitagawa, Koh; Moriya, Kei; Kaji, Kosuke; Saikawa, Soichiro; Sato, Shinya; Nishimura, Norihisa; Namisaki, Tadashi; Akahane, Takemi; Mitoro, Akira; Yoshiji, Hitoshi
2020年6月19日	Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis.	Tsuji, Yuki; Kaji, Kosuke; Kitade, Mitsuteru; Kaya, Daisuke; Kitagawa, Koh; Ozutsumi, Takahiro; Fujinaga, Yukihisa; Takaya, Hiroaki; Kawaratani, Hideto; Namisaki, Tadashi; Moriya, Kei; Akahane, Takemi; Yoshiji, Hitoshi
2019年12月	Combination of L-Carnitine and Angiotensin-II type 1 Receptor Blocker has Beneficial Effects on Hepatic Fibrosis in a Non-Alcoholic Steatohepatitis Rat Model.	Kubo, Takuya; Kawaratani, Hideto; Sawada, Yasuhiko; Fujinaga, Yukihisa; Ozutsumi, Takahiro; Kaya, Daisuke; Tsuji, Yuki; Nakanishi, Keisuke; Furukawa, Masanori; Kitagawa, Kou; Saikawa, Soichiro; Sato, Shinya; Takaya, Hiroaki; Kaji, Kosuke; Shimozato, Naotaka; Moriya, Kei; Namisaki, Tadashi; Akahane, Takemi; Mitoro, Akira; Yoshiji, Hitoshi
2019年10月	Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis.	Shimozato, Naotaka; Namisaki, Tadashi; Kaji, Kosuke; Kitade, Mitsuteru; Okura, Yasushi; Sato, Shinya; Moriya, Kei; Seki, Kenichiro; Kawaratani, Hideto; Takaya, Hiroaki; Sawada, Yasuhiko; Saikawa, Soichiro; Nakanishi, Keisuke; Furukawa, Masanori; Fujinaga, Yukihisa; Kubo, Takuya; Asada, Kiyoshi; Kitagawa, Koh; Tsuji, Yuki; Kaya, Daisuke; Ozutsumi, Takahiro; Akahane, Takemi; Mitoro, Akira; Yoshiji, Hitoshi
2016年12月28日	Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis.	Okura, Yasushi; Namisaki, Tadashi; Moriya, Kei; Kitade, Mitsuteru; Takeda, Kosuke; Kaji, Kosuke; Noguchi, Ryuichi; Nishimura, Norihisa; Seki, Kenichiro; Kawaratani, Hideto; Takaya, Hiroaki; Sato, Shinya; Sawada, Yasuhiko; Shimozato, Naotaka; Furukawa, Masanori; Nakanishi, Keisuke; Saikawa, Soichiro; Kubo, Takuya; Asada, Kiyoshi; Yoshiji, Hitoshi
2020年3月21日	Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis.	Ozutsumi, Takahiro; Namisaki, Tadashi; Shimozato, Naotaka; Kaji, Kosuke; Tsuji, Yuki; Kaya, Daisuke; Fujinaga, Yukihisa; Furukawa, Masanori; Nakanishi, Keisuke; Sato, Shinya; Sawada, Yasuhiko; Saikawa, Soichiro; Kitagawa, Koh; Takaya, Hiroaki; Kawaratani, Hideto; Kitade, Mitsuteru; Moriya, Kei; Noguchi, Ryuichi; Akahane, Takemi; Mitoro, Akira; Yoshiji, Hitoshi
2008年1月	Different tumoricidal effects of interferon subclasses and p53 status on hepatocellular carcinoma development and neovascularization.	Noguchi, Ryuichi; Yoshiji, Hitoshi; Ikenaka, Yasuhide; Kitade, Mitsuteru; Kaji, Kosuke; Yoshii, Junichi; Yanase, Koji; Namisaki, Tadashi; Yamazaki, Masaharu; Tsujimoto, Tatsuhiro; Akahane, Takemi; Uemura, Masahito; Fukui, Hiroshi
2013年11月	Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model.	Aihara, Yosuke; Yoshiji, Hitoshi; Noguchi, Ryuichi; Kaji, Kosuke; Namisaki, Tadashi; Shirai, Yusaku; Douhara, Akitoshi; Moriya, Kei; Kawaratani, Hideto; Fukui, Hiroshi
2021年12月28日	Dual therapy with zinc acetate and rifaximin prevents from ethanolinduced liver fibrosis by maintaining intestinal barrier integrity	Fujimoto, Yuki; Kaji, Kosuke; Nishimura, Norihisa; Enomoto, Masahide; Murata, Koji; Takeda, Soichi; Takaya, Hiroaki; Kawaratani, Hideto; Moriya, Kei; Namisaki, Tadashi; Akahane, Takemi; Yoshiji, Hitoshi
2020年8月4日	Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis.	Fujinaga, Yukihisa; Kawaratani, Hideto; Kaya, Daisuke; Tsuji, Yuki; Ozutsumi, Takahiro; Furukawa, Masanori; Kitagawa, Koh; Sato, Shinya; Nishimura, Norihisa; Sawada, Yasuhiko; Takaya, Hiroaki; Kaji, Kosuke; Shimozato, Naotaka; Moriya, Kei; Namisaki, Tadashi; Akahane, Takemi; Mitoro, Akira; Yoshiji, Hitoshi
2023年10月	Glucagon-like peptide-1 receptor agonist, semaglutide attenuates chronic liver disease-induced skeletal muscle atrophy in diabetic mice	Iwai, Satoshi; Kaji, Kosuke; Nishimura, Norihisa; Kubo, Takahiro; Tomooka, Fumimasa; Shibamoto, Akihiko; Suzuki, Junya; Tsuji, Yuki; Fujinaga, Yukihisa; Kitagawa, Koh; Namisaki, Tadashi; Akahane, Takemi; Yoshiji, Hitoshi
2021年4月	Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis.	Ogawa, Hiroyuki; Kaji, Kosuke; Nishimura, Norihisa; Takagi, Hirotetsu; Ishida, Koji; Takaya, Hiroaki; Kawaratani, Hideto; Moriya, Kei; Namisaki, Tadashi; Akahane, Takemi; Yoshiji, Hitoshi
2018年6月19日	Oral administration of fructose exacerbates liver fibrosis and hepatocarcinogenesis via increased intestinal permeability in a rat steatohepatitis model.	Seki, Kenichiro; Kitade, Mitsuteru; Nishimura, Norihisa; Kaji, Kosuke; Asada, Kiyoshi; Namisaki, Tadashi; Moriya, Kei; Kawaratani, Hideto; Okura, Yasushi; Takaya, Hiroaki; Sawada, Yasuhiko; Sato, Shinya; Nakanishi, Keisuke; Yoshiji, Hitoshi
2017年11月	Periostin cross‑reacts with the renin‑angiotensin system during liver fibrosis development.	Takeda, Kosuke; Noguchi, Ryuichi; Kitade, Mitsuteru; Namisaki, Tadashi; Moriya, Kei; Kawaratani, Hideto; Okura, Yasushi; Kaji, Kosuke; Aihara, Yosuke; Douhara, Akitoshi; Nishimura, Norihisa; Sawada, Yasuhiko; Seki, Kenichiro; Yoshiji, Hitoshi
2015年3月	Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model.	Douhara, Akitoshi; Moriya, Kei; Yoshiji, Hitoshi; Noguchi, Ryuichi; Namisaki, Tadashi; Kitade, Mitsuteru; Kaji, Kosuke; Aihara, Yosuke; Nishimura, Norihisa; Takeda, Kosuke; Okura, Yasushi; Kawaratani, Hideto; Fukui, Hiroshi
2022年10月	Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet–induced rat steatohepatitis	Enomoto, Masahide; Kaji, Kosuke; Nishimura, Norihisa; Fujimoto, Yuki; Murata, Koji; Takeda, Soichi; Tsuji, Yuki; Fujinaga, Yukihisa; Tanaka, Hiroaki; Kawaratani, Hideto; Namisaki, Tadashi; Akahane, Takemi; Yoshiji, Hitoshi
2022年8月	Rifaximin enhances the L‑carnitine‑mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut‑liver‑muscle axis	Murata, Koji; Kaji, Kosuke; Nishimura, Norihisa; Enomoto, Masahide; Fujimoto, Yuki; Takeda, Soichi; Tsuji, Yuki; Fujinaga, Yukihisa; Takaya, Hiroaki; Kawaratani, Hideto; Namisaki, Tadashi; Akahane, Takemi; Yoshiji, Hitoshi